Abstract 17P
Background
Triple negative (TNBC) is the most aggressive subtype of breast cancer, lacking effective targeted therapies. PARP inhibitors (PARPi) like olaparib, in combination with immune checkpoint inhibitors, stand out among the groundbreaking strategies to treat BRCA1/2 mutated TNBC but are often connected to resistance.
Methods
Western blot, coimmunoprecipitation, qPCR, immunofluorescence, proliferation and cytotoxicity assays.
Results
Our preclinical results unprecedentedly show that connexin43 (Cx43) upregulation in Cx43-null BRCA1 mutated TNBC cells, de novo resistant to PARPi olaparib, deeply resensitizes them, reducing their IC50 almost by half as well as their 2D and physiologically-appropriate 3D spheroid proliferation upon treatment with the drug. Consistent with this, olaparib therapy reduces global protein PARylation and induces significantly higher levels of DNA double-strand damage, PARP1 cleavage and caspase 3-mediated apoptosis in Cx43-restored cells, emphasizing their higher susceptibility to PARPi. Similar results were obtained under physiologically-relevant Anoikis conditions and in BRCA1 mutated ovarian cancer cells. Wild type but not Cx43-restituted cells accumulate RAD51 foci after drug treatment, denoting a potential underlying mechanism of resistance. In order to validate our proposal, an innovative extracellular vesicle-based approach was developed as an avant-garde translational strategy to efficiently deliver both Cx43 and PARPi drug to tumour cells. Combination of olaparib with Cx43-enriched vesicles distinctively enhanced olaparib efficacy against de novo resistant BRCA1 mutated TNBC cells versus the drug alone. In addition, in cocultures of patient-derived and EGFR-CAR(chimeric-antigen-receptor)-engineered natural killer (NK) cells with BRCA1 mutated TNBC cells, Cx43 restoration in tumour cells elicited a significantly higher cytotoxic NK antitumour response than wild type cells.
Conclusions
These results, protected by a EU patent, reveal Cx43 as a dual promising novel therapeutic target to increase the efficacy and to resensitize de novo resistant BRCA1 mutated TNBC to PARPi olaparib, as well as to boost NK cytotoxicity against TNBC.
Clinical trial identification
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
Ministerio de Universidades, European Molecular Biology Organization, Xunta de Galicia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
53P - Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation
Presenter: Francesco Bertoni
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Inhibition of ATM vs ATR in combination with radiotherapy affects cellular toxicity and expression of immune checkpoint molecules differently in HNSCC
Presenter: Tina Jost
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells
Presenter: Martin Hohenegger
Session: Cocktail & Poster Display session
Resources:
Abstract
56P - Inhibition of HIF-2α-dependent transcription with small molecule inhibitors may provide therapeutic benefit beyond renal cell carcinoma
Presenter: Kelsey Gauthier
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Deciphering the role of E2F transcription factor-1 in glutamine metabolism
Presenter: Katharina Huber
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low-expressing breast cancer cells and organoid mode
Presenter: Maryam Arshad
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - The influence of the ABCB1, ABCG2 and OATP1 transporters and the CYP3A enzyme on the bioavailability and tissue distribution of TPX-0131
Presenter: Jamie Rijmers
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - MAPKAP1/SIN1: A promising therapeutic target in resistant BRAF-mutated melanoma
Presenter: Emilien Ezine
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - The cysteine-rich protein 61 (Cyr61) contributes to tumor proliferation and invasion via HGF-mediated NF-kB signaling pathway in human hepatocellular carcinoma
Presenter: Jiyoon Jung
Session: Cocktail & Poster Display session
Resources:
Abstract
62P - Anti-malarial drug quinacrine: A potential molecule for repurposing in targeting human non-small cell lung cancer cells (NSCLC)
Presenter: ANGSHUMAN SARKAR
Session: Cocktail & Poster Display session
Resources:
Abstract